FORM NHAMCS-906

U.S. DEPARTMENT OF COMMERCE Economics and Statistics Administration U.S. CENSUS BUREAU ACTING AS DATA COLLECTION AGENT FOR THE
U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
National Center for Health Statistics

NATIONAL HOSPITAL AMBULATORY **MEDICAL CARE SURVEY** 2007 CERVICAL CANCER SCREENING SUPPLEMENT

NOTICE – Public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road, MS D-74, Atlanta, GA 30333, ATTN: PRA(0920-0278).

Assurance of Confidentiality - All information which would permit identification of an individual, a practice, or an establishment will be held confidential, will be used by persons engaged in and for the purpose of the survey and will not be disclosed or released to other persons or used for any other purpose without the consent of the individual or the establishment in accordance with section 308(d) of the Public Health Service Act (42 USC 242m).

BACKGROUND INFORMATION

A. Hospital's name		B. Hospital number								
0020 C. OPD Clinic name			0025 D. Clinic type – Mark (X) only ONE.							
				1 OB/0	GYN	2 🗌 GN	Л			
0030 E. AU number	ne		G. OPD conta	Clinic Area code Number ct telephone						
0040 H. Census contact name		0045	L Censi conta		s Area code Number ttelephone					
The Centers for Disease Control and Prevention is conducting a special survey on cervical cancer screening performed in hospital outpatient clinics. Please answer the following questions. We appreciate your time on this important public health concern.										
You have the option to complete this questionnaire on the Internet. Go to www.cdc.gov/nhamcs , select the link for the 2007 version of the Cervical Cancer Supplement, enter the User ID and Password displayed, and follow the instructions. User ID Password										
A Dear Main aliais was assurable	a fallacciono canta a da ta accesa fa				Mark (X) one inte	erval for i	outine so	reening.	
cervical cancer? Mark (X) all that apply.	ne following methods to screen fo ition – Smear spread on glass slic		nd fix	ed)	 Annually 	Every 2 years	Every 3 years	More than 3 years	No routine interval recom- mended	
1 Yes – How often does your clinic routinely screen women using this method? 2 No 3 Unknown Continue with item 1b					1	2	з□	4	5	
b. Liquid-based cytology (Definition – Specimen suspended in liquid solution) Ooeo					 	2	з□	4	5	
c. Other – <i>Specify</i> ✓					1					
5005										
1 Yes – How often does y method? 2 No 3 Unknown	our clinic routinely screen womer	n usin	g thi	S	 	2	3 🗆	4	5 🗆	
U S C E N S U S B U R E A	\ II									

2. Does this clinic perform colposcopy? 0050	does this clinic routinely order an HPV DNA test to be performed on that sample (commonly called reflex HPV DNA testing)? (An HPV DNA test may be run on the same liquid-based medium as the Pap test or an HPV DNA test specimen may be collected at the same time as the conventional Pap test.) 1 Yes – Go to item 4b 2 No 3 Unknown 3 KIP to item 5a
b. Which of the following HPV DNA tests are ordered or collected in this clinic? Mark (X) all that apply. 1	For which borderline or abnormal Pap test result would this clinic order or collect a reflex HPV DNA test? Mark (X) all that apply. Dogo 1 ASC-US (atypical squamous cells of undetermined significance) ASC-H (atypical squamous cells of undetermined significance – cannot exclude high-grade intraepithelial lesion) LSIL (low-grade squamous intraepithelial lesion, encompassing mild dysplasia/CIN1) HSIL (high-grade squamous intraepithelial lesion, moderate dysplasia/CIN2, severe dysplasia/CIN3, and carcinoma in situ) AGC (atypical glandular cells)
 This clinic does not see the types of patients for whom the HPV DNA test is indicated. This clinic uses other tests, procedures, or examination methods to manage patients for whom the HPV DNA test is indicated. The patients in this clinic have timely access to colposcopy. Assessing patients' HPV infection status is not a priority at this clinic. 	For which patients does this clinic usually order reflex HPV DNA testing? – Mark (X) all that apply. 1 Women under 30 years old 2 Women 30 years old and over 3 Other – Specify 5010
 The labs affiliated with this clinic do not offer the HPV DNA test. The health plans or health systems affiliated with this clinic do not recommend the HPV DNA test. The HPV DNA test is not a reimbursed or covered service for most patients in this clinic. Discussing cervical cancer screening in the context 	 5a. Does this clinic routinely recall patients to come back for a second sample collection for an HPV DNA test if their Pap test is abnormal or borderline (recall testing)? □ 1□ Yes – Go to item 5b □ No □ Unknown SKIP to item 6a on page 3
of an STD is avoided in this clinic. 9 Notifying or counseling patients about positive HPV DNA test results would take too much time. 10 Notifying or counseling patients about positive HPV DNA test results might make clinicians in this clinic feel uncomfortable. 11 Notifying or counseling patients about positive HPV DNA test results might make patients in this clinic feel uncomfortable, angry, or upset. SKIP to item 7 on page 3.	b. For which abnormal or borderline Pap test result would this clinic recall a patient for an HPV DNA test? Mark (X) all that apply. 1 ASC-US (atypical squamous cells of undetermined significance) 2 ASC-H (atypical squamous cells of undetermined significance – cannot exclude high-grade intraepithelial lesion) 3 LSIL (low-grade squamous intraepithelial lesion, encompassing mild dysplasia/CIN1) 4 HSIL (high-grade squamous intraepithelial lesion, moderate dysplasia/CIN2, severe dysplasia/CIN3, and carcinoma in situ) 5 AGC (atypical glandular cells)

Page 2 FORM NHAMCS-906 (11-3-2006)

6a.	6a. Does this clinic routinely order or collect an HPV DNA test at the same time as the Pap test as part of routine cervical cancer screening (commonly called adjunct HPV testing or cotesting)?										
0110	1 🔲 '	Yes – Go to item 6b									
	2 No SKIP to item 7										
	3 🔲	Unknown J OKII 18) item /								
b.	For which patients does this clinic routinely order or collect an HPV DNA test along with the Pap test (commonly called adjunct HPV testing or cotesting)? Mark (X) all that apply.										
0115	1 🗆 🕽	Women under 30 yea	ars old								
		Women 30 years old									
	3 🗆 1	Women who request test for cervical canc	the								
		screening	01								
	4☐ Women who request the test to check their HPV infection status										
	5 ☐ Other – Specify ⊋										
5015											
7.	7. Given the following screening histories, when would this clinic recommend that a woman between 30 and 60 years of age return for her next Pap test?										
			1		For ea	ch of the fo	llowing scen	arios, mai	rk (X) only	ONE for ea	ch row.
		ap test results I st 5 years	Current HPV	Current							Have no experience
	exclu	uding current	DNA test	Pap test	No follow-up	Less than 6 months	6 months to less	1 year	2 years	3 years	with this type of
	norr	mal results)	results	result	needed	O IIIOIIIIIS	than 1 year	year	years	or more	patient or
0120	/-\	T									test
0120	(a)	Two consecutive normal Pap tests	Has not had test	Normal	1 🗆	2	3□	4	5 🗌	6 🗆	7
0125	(b)	Two consecutive									
	,	normal Pap tests	Negative	Normal	1 🗌	2	3 🗌	4	5 🗌	6	7
0130	(c)	Two consecutive	ĺ								
		normal Pap tests	Positive	Normal	1 🗆	2	3 🗆	4	5 🗌	6 🗆	7
0135	(d)	Has not had a Pap	' :								
		test	Negative	Normal	1 🗆	2 🗌	3 🗆	4 🗌	5 🗌	6 🗆	7 🗆
0140	(e)	Has not had a Pap test	Positive	Normal	1 🗆	2	3□	4	5 🗌	6	7
0145	(f)	Abnormal Pap test	Negative	Normal	1 🗌	2	3 🗆	4	5	6	7
0150	(g)	Abnormal Pap test	Positive	Normal	1 🗆	2	з□	4	5 🗌	6 🗆	7
	QUESTIONS 8–10 ASK ABOUT THE HPV VACCINE										
8. How often does your clinic use an HPV test to determine who should get the HPV vaccine? Mark (X) only one.											
1 ☐ Rarely or never											
2 ☐ Sometimes											
3 ☐ Usually											
	4 ☐ Always or almost always 5 ☐ Do not recommend the HPV vaccine <i>–SKIP to item 10.</i>										
	SE DO NOCTOSSITITIONS IN THE VACCING ONLY TO REM TO.										

FORM NHAMCS-906 (11-3-2006) Page 3

9.	As it relates to the HPV vaccine, how often does your clinic –								
	Mark (X) only ONE for each row.	Rarely or never	Sometimes	Usually	Always or almost always	Unknown/not applicable/			
0120	a. Use the number of sexual partners to				,	Do not ask			
	determine who should get the HPV vaccine?	1 🗌	2	з 🗌	4 🗆	5 🗌			
0125	b. Perform a Pap test to determine who should get the HPV vaccine?	1 🗆	2	3□	4 🗆	5			
0130	c. Recommend the HPV vaccine to females with a history of an abnormal Pap test result (ASC-US or higher)?	1 🗆	2 🗆	3 🗆	4 🗌	5 🗌			
0135	d. Recommend the HPV vaccine to females with a positive HPV test?	1 🗌	2	3□	4 🗆	5			
10.	Mill your clinic's cervical cancer screening and management procedures change for females who have been fully vaccinated with the HPV vaccine? □ Yes □ No − SKIP to item 14								
11.	11. How will your clinic determine when to start routine cervical cancer screening for fully HPV vaccinated females? 1 □ By age 1 □ At same age as non-HPV vaccinated females −								
	Mark (X) all that apply.	 	Specify a 2□ At a later	age –					
		İ	Specify a 2☐ By onset of s	•	→				
		[2 ☐ By onset of sexual activity — How many year(s) since onset of sexual activity?——→						
		İ	3☐ Will not be screening fully HPV vaccinated females						
	4 ☐ Unknown								
12.		often will your clinic routinely screen for cervical er among females that have been fully vaccinated he HPV vaccine? Mark (X) one. Annually Every 2–3 years Every 4–5 years Greater than every 5 years Will not be screening fully HPV vaccinated females Greater than every 5 years Unknown							
13.	Will your clinic be using the HPV DNA test for managing abnormal cytology for females that have been fully vaccinated with the HPV vaccine? 1 ☐ Yes 2 ☐ No								
14.	Please indicate to what extent you agree, diwith each statement. Please respond to both	Agree	Disagree	Unsure					
	There will be fewer numbers of abnorm among vaccinated females.	1 🗆	2 🗆	з□					
	b. There will be fewer referrals for colpose vaccinated females.	1 🗆	2	з 🗆					
	15. The Centers for Disease Control and Prevention (CDC) funds state health departments to provide breast and cervical cancer screening services to low income women through the National Breast and Cervical Cancer Early Detection Program (Title XV). The state health departments contract out the screening services to physicians and other health care providers. Is this clinic currently participating in this state or national screening program?								
0155									
0160	16. For purposes of this survey, which of the following categories describe your profession? – <i>Mark (X) only ONE.</i> □160 1 □ Physician 2 □ Physician assistance/ 3 □ Registered nurse 4 □ Other clinic staff								
	Nurse practitioner/ Nurse midwife								

CLOSING STATEMENT

Thank you for completing this special survey. We appreciate your time and cooperation.

Page 4 FORM NHAMCS-906 (11-3-2006)